A prospective evaluation of the association between a single nucleotide polymorphism rs3775291 in toll-like receptor 3 and breast cancer relapse

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Chen, Dan Na ^a,b   Song, Chuan Gui ^a   Yu, Ke Da ^b   Jiang, Yi Zhou ^b   Ye, Fu Gui ^a   Shao, Zhi Ming ^b  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TOLL LIKE RECEPTOR 3; TLR3 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 1; TUMOR MARKER;

ADULT; ALLELE; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER SURVIVAL; CHINESE; COHORT ANALYSIS; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; RECURRENCE FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; TRIPLE NEGATIVE BREAST CANCER; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MODEL; BREAST TUMOR; CHINA; DISEASE FREE SURVIVAL; DOMINANT GENE; EPIDEMIOLOGY; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MISSENSE MUTATION; MORTALITY; RECESSIVE GENE; TUMOR RECURRENCE;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CHINA; DISEASE-FREE SURVIVAL; FEMALE; GENES, DOMINANT; GENES, RECESSIVE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MODELS, GENETIC; MUTATION, MISSENSE; NEOPLASM RECURRENCE, LOCAL; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; TOLL-LIKE RECEPTOR 1; TOLL-LIKE RECEPTOR 3; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84942134070     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0133184     Document Type: Article

References (29)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA: A Cancer Journal for Clinicians 61: 69-90.
2. Kennecke H, Yerushalmi R, Woods R, Cheang MCU, Voduc D, et al. (2010) Metastatic Behavior of Breast Cancer Subtypes. Journal of Clinical Oncology 28: 3271-3277. doi: 10.1200/JCO.2009.25. 9820 PMID: 20498394
3. Kidd LR, Rogers EN, Yeyeodu ST, Dominique Jones D, Kimbro KS (2013) Contribution of toll-like receptor signaling pathways to breast tumorigenesis and treatment. Breast Cancer: Targets and Therapy: 43.
4. Costantini S, Capone F, Guerriero E, Castello G (2009) An approach for understanding the inflammation and cancer relationship. Immunology Letters 126: 91-92. doi: 10.1016/j.imlet.2009.08.006 PMID: 19699235
5. Basith S, Manavalan B, Yoo TH, Kim SG, Choi S (2012) Roles of toll-like receptors in Cancer: A double-edged sword for defense and offense. Archives of Pharmacal Research 35: 1297-1316. doi: 10. 1007/s12272-012-0802-7 PMID: 22941474
6. Kawai T, Akira S (2006) TLR signaling. Cell Death and Differentiation 13: 816-825. PMID: 16410796
7. Sato Y, Goto Y, Narita N, Hoon DSB (2009) Cancer Cells Expressing Toll-like Receptors and the Tumor Microenvironment. Cancer Microenvironment 2: 205-214. doi: 10.1007/s12307-009-0022-y PMID: 19685283
8. Chang ZL (2010) Important aspects of Toll-like receptors, ligands and their signaling pathways. Inflammation Research 59: 791-808. doi: 10.1007/s00011-010-0208-2 PMID: 20593217
9. González-Reyes S, Marín L, González L, González LO, del Casar JM, et al. (2010) Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer 10: 665. doi: 10.1186/1471-2407-10-665 PMID: 21129170
10. Salaun B, Zitvogel L, Asselin-Paturel C, Morel Y, Chemin K, et al. (2011) TLR3 as a Biomarker for the Therapeutic Efficacy of Double-stranded RNA in Breast Cancer. Cancer Research 71: 1607-1614. doi: 10.1158/0008-5472.CAN-10-3490 PMID: 21343393
11. Schröder NWJ, Schumann RR (2005) Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. The Lancet Infectious Diseases 5: 156-164. PMID: 15766650
12. Zeljic K, Supic G, Jovic N, Kozomara R, Brankovic-Magic M, et al. (2014) Association of TLR2, TLR3, TLR4 and CD14 genes polymorphisms with oral cancer risk and survival. Oral Diseases 20: 416-424. doi: 10.1111/odi.12144 PMID: 23796347
13. Castro FA, Försti A, Buch S, Kalthoff H, Krauss C, et al. (2011) TLR-3 polymorphism is an independent prognostic marker for stage II colorectal cancer. European Journal of Cancer 47: 1203-1210. doi: 10. 1016/j.ejca.2010.12.011 PMID: 21239167
14. Dai J, Hu Z, Dong J, Xu L, Pan S, et al. (2012) Host immune gene polymorphisms were associated with the prognosis of non-small-cell lung cancer in Chinese. International Journal of Cancer 130: 671-676.
15. Kutikhin AG (2011) Association of polymorphisms in TLR genes and in genes of the Toll-like receptor signaling pathway with cancer risk. Human Immunology 72: 1095-1116. doi: 10.1016/j.humimm.2011. 07.307 PMID: 21872627
16. Yu KD, Di GH, Fan L, Wu J, Hu Z, et al. (2009) A functional polymorphism in the promoter region of GSTM1 implies a complex role for GSTM1 in breast cancer. The FASEB Journal 23: 2274-2287. doi: 10.1096/fj.08-124073 PMID: 19228880
17. Yu K-D, Fan L, Di G-H, Yuan W-T, Zheng Y, et al. (2009) Genetic variants in GSTM3 gene within GSTM4-GSTM2-GSTM1-GSTM5-GSTM3 cluster influence breast cancer susceptibility depending on GSTM1. Breast Cancer Research and Treatment 121: 485-496. doi: 10.1007/s10549-009-0585-9 PMID: 19856098
18. Yu KD, Di GH, Yuan WT, Fan L, Wu J, et al. (2009) Functional polymorphisms, altered gene expression and genetic association link NRH:quinone oxidoreductase 2 to breast cancer with wild-type p53. Human Molecular Genetics 18: 2502-2517. doi: 10.1093/hmg/ddp171 PMID: 19351655
19. Yin W, Di G, Zhou L, Lu J, Liu G, et al. (2009) Time-varying pattern of recurrence risk for Chinese breast cancer patients. Breast Cancer Res Treat 114: 527-535. doi: 10.1007/s10549-008-0022-5 PMID: 18425576
20. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, et al. (2005) Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16: 1569-1583. PMID: 16148022
21. Goldhirsch A, Glick JH, Gelber RD, Senn HJ (1998) Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst 90: 1601-1608. PMID: 9811309
22. McShane LM, Hayes DF (2012) Publication of Tumor Marker Research Results: The Necessity for Complete and Transparent Reporting. Journal of Clinical Oncology 30: 4223-4232. doi: 10.1200/JCO. 2012.42.6858 PMID: 23071235
23. Bell PA, Chaturvedi S, Gelfand CA, Huang CY, Kochersperger M, et al. (2002) SNPstream UHT: ultrahigh throughput SNP genotyping for pharmacogenomics and drug discovery. Biotechniques Suppl: 70-72, 74, 76-77.
24. Sun J, Duffy KE, Ranjith-Kumar CT, Xiong J, Lamb RJ, et al. (2006) Structural and Functional Analyses of the Human Toll-like Receptor 3: ROLE OF GLYCOSYLATION. Journal of Biological Chemistry 281: 11144-11151. PMID: 16533755
25. Zhou P, Fan L, Yu KD, Zhao MW, Li XX (2011) Toll-like receptor 3 C1234T may protect against geographic atrophy through decreased dsRNA binding capacity. The FASEB Journal 25: 3489-3495. doi: 10.1096/fj.11-189258 PMID: 21712495
26. Zhenglin Yang CS, Francis PJ, Kleinman ME, Tan PL, et al. (2008) Toll-like Receptor 3 and Geographic Atrophy in Age-Related Macular Degeneration. N Engl J Med: 1456-1463. doi: 10.1056/NEJMoa0802437 PMID: 18753640
27. Voduc KD, Cheang MCU, Tyldesley S, Gelmon K, Nielsen TO, et al. (2010) Breast Cancer Subtypes and the Risk of Local and Regional Relapse. J Clin Oncol 28: 1684-1691. doi: 10.1200/JCO.2009.24. 9284 PMID: 20194857
28. Yuzhalin A, Kutikhin A (2012) Are Toll-like receptor gene polymorphisms associated with prostate cancer? Cancer Management and Research: 23. doi: 10.2147/CMAR.S28683 PMID: 22359464
29. Ahuja SK, Chantratita N, Tandhavanant S, Myers ND, Chierakul W, et al. (2014) Common TLR1 Genetic Variation Is Not Associated with Death from Melioidosis, a Common Cause of Sepsis in Rural Thailand. PLoS ONE 9: e83285. doi: 10.1371/journal.pone.0083285 PMID: 24392083